Radiation sensitizer or anti-cancer chemotherapy sensitizer

Abstract

The present invention provides a novel radiosensitizer or anti-cancer chemotherapy sensitizer. In particular, the invention provides a radiosensitizer or anti-cancer chemotherapy sensitizer that can relieve the irritation of an affected area caused by hydrogen peroxide, is safe when injected into a human body, and can delay or reduce the degradation of hydrogen peroxide and thereby can efficiently exert a radiation sensitizing effect and an anti-cancer chemotherapy sensitizing effect. The radiosensitizer or anti-cancer chemotherapy sensitizer comprises a combination of (a) hydrogen peroxide and (b) hyaluronic acid or salt thereof.

1 - 21 . (canceled) 
     
     
         22 . A method of treating cancer in a patient comprising:
 (1) a step of applying to a tumor a composition comprising (a) 0.01 to 3.5 weight percent of hydrogen peroxide in a final formulation and (b) a gelatin, wherein applying the composition is an intratumoral injection, and   (2) a step of performing a radiotherapy treatment or an anti-cancer chemotherapy treatment at the same time as or after the step (1),   wherein the composition delays or reduces degradation of the hydrogen peroxide in the tumor and reduces irritation of the hydrogen peroxide at the time of the injection.   
     
     
         23 . The method of treating cancer according to  claim 22 , wherein the tumor is resistant to the radiotherapy treatment or resistant to the anti-cancer chemotherapy treatment. 
     
     
         24 . The method of treating cancer according to  claim 22 , wherein the radiotherapy treatment is performed and comprises irradiation with an X-ray beam or electron beam from a linear accelerator. 
     
     
         25 . The method of treating cancer according to  claim 22 , wherein the anti-cancer chemotherapy treatment is performed and comprises administering an anti-cancer agent to the patient. 
     
     
         26 . The method of treating cancer according to  claim 22 , wherein a content of the gelatin in a final formulation of the composition is 0.1 to 10 weight percent. 
     
     
         27 . The method according to  claim 22 , wherein the concentration of the hydrogen peroxide in the final formulation is 0.1 to 2 weight percent. 
     
     
         28 . The method according to  claim 22 , wherein the concentration of the hydrogen peroxide in the final formulation is 0.36 to 2 weight percent. 
     
     
         29 . The method according to  claim 22 , wherein the intratumoral injection of the composition comprises guidance from an ultrasonographic examination while observing a state of permeation of the composition into the tumor. 
     
     
         30 . The method according to  claim 22 , wherein the composition consists of:
 (a) 0.1 to 2 weight percent of hydrogen peroxide in a final formulation;   (b) the gelatin; and   optionally (c) at least one component selected from the group consisting of water, L-methionine, sodium chloride, sodium hydrogenphosphate, crystalline sodium dihydrogen phosphate, glycerin, glucose, polyethylene glycol, propylene_glycol, D-mannitol, fructose, xylitol, sodium dihydrogen phosphate, sodium phosphate, hydrochloric acid, sodium hydroxide, a phosphoric acid buffer solution, a tris buffer solution, and an acetic acid buffer solution.